How Long to Wait to Drink After Taking a Muscle Relaxer? – Muscle relaxers like cyclobenzaprine usually last around four to six hours. Cyclobenzaprine has a half-life that ranges between eight to 37 hours for most adults. The half-life of a substance is the amount of time it takes for your body to metabolize half of the medication and remove it from your body.
Your age How your liver functions Your metabolism
Muscle relaxers stay in your system longer than 24 hours. If you must have an alcoholic beverage, it is best to wait 24 hours or longer after taking your last dose of the muscle relaxer to avoid any potentially harmful effects.
Contents
- 1 Can I take a muscle relaxer if I had a glass of wine?
- 2 How long to wait after taking cyclobenzaprine?
- 3 Can I take cyclobenzaprine if I had a glass of wine?
- 4 Is 10 mg of cyclobenzaprine strong?
- 5 What happens if you drink alcohol with a muscle relaxer on an empty stomach?
- 6 Is cyclobenzaprine hard on the liver?
- 7 Is alcohol a natural muscle relaxer?
- 8 Can I take cyclobenzaprine during the day?
- 9 Why can’t you drive on cyclobenzaprine?
- 10 Does cyclobenzaprine affect serotonin levels?
- 11 What to avoid while taking cyclobenzaprine?
Can you drink alcohol after taking cyclobenzaprine?
Treatment for Addiction to Flexeril and Alcohol – Flexeril is an effective pharmacological treatment for muscle spasms and pain, but it can lead to an increased risk of side effects and dependency when mixed with alcohol. If you or a loved one has been prescribed Flexeril but are no longer using it as prescribed or you’re combining it with alcohol, it may be time to seek help.
Can I take a muscle relaxer if I had a glass of wine?
The Effects of Mixing Alcohol and Muscle Relaxers – When alcohol and muscle relaxers are mixed together, the effects can be quite dangerous. Not only do muscle relaxers and alcohol both have sedative effects on the body, but they also share common side effects such as dizziness, drowsiness, nausea, and impaired coordination.
- When a person takes alcohol and muscle relaxers together, the effects of these drugs become even stronger.
- Mixing alcohol with muscle relaxers has different effects in both the short and long term.
- In the short term, there are many concerning effects.
- These mostly have to do with impairment and motor control.
Some of these effects are:
Dizziness Drowsiness Nausea Impaired coordination
All of these effects make it dangerous to operate machinery or drive a car. It is also easy to fall and hurt yourself if you are not careful. Poor vision and confusion are also a risk for people who mix alcohol and muscle relaxers. The ability of these drugs to depress the central nervous system can lead to the inability to think clearly.
Individuals may experience impaired judgment, dangerous mood swings, and even aggressive behaviors. While the short-term effects of mixing these two substances together are serious, the long-term effects are even more concerning. As with any substance, a significant risk is posed by continually ingesting a drug.
This goes for many prescription medications and for alcohol, Many internal organs experience damage due to mixing these substances. Further, mixing alcohol and muscle relaxers puts women at an increased risk of developing a substance use disorder. Other dangers include the following:
Liver damage : Mixing alcohol and muscle relaxers will cause damage to the liver. When these substances are both present in the body, the liver—which is responsible for processing both—works overtime. Addiction : Combining muscle relaxers and alcohol can lead to addiction. This is because both substances act on the brain’s reward center, causing a person to feel pleasurable effects. Overdose : Mixing alcohol with muscle relaxers can also lead to an overdose. This is especially true if a person takes more than the recommended amount of either substance. Respiratory depression can occur, causing an individual to stop breathing. Alcohol poisoning : Combining muscle relaxers with alcohol can also cause alcohol poisoning. This is a serious, potentially life-threatening condition that occurs when a person drinks too much alcohol in a short period of time. Symptoms include vomiting, seizures, and blackouts. Gastrointestinal damage : Prescription medication and alcohol both cause damage to the GI tract. Over time, alcohol can cause inflammation and scarring in the lining of the GI tract. While muscle relaxers are often used to reduce intense abdominal pain, over time they can have negative side effects such as ulcers, hemorrhoids, constipation, or diarrhea.
Overall, it is clear that alcohol and muscle relaxers should not be mixed together. Whether you are taking these substances for recreational or medical reasons, the potential negative consequences far outweigh any perceived benefits.
How long to wait after taking cyclobenzaprine?
Some people start to feel the effects within 30 minutes, but you should definitely feel the effects within an hour. The long-acting Amrix (cyclobenzaprine) capsules take a little longer to work but last for up to 24 hours. Most people start to feel the effects about a hour and a half after they take their dose.
Can you drink alcohol with PMS cyclobenzaprine 10 mg?
How to use this medication – The dosage of this medication depends on what it is used for. Depending on the circumstance, it may be used regularly or only as needed. Follow the instructions provided by your doctor or pharmacist. This medication may irritate the stomach, and should be taken with food.
Can I drink 12 hours after taking cyclobenzaprine?
How Long to Wait to Drink After Taking a Muscle Relaxer? – Muscle relaxers like cyclobenzaprine usually last around four to six hours. Cyclobenzaprine has a half-life that ranges between eight to 37 hours for most adults. The half-life of a substance is the amount of time it takes for your body to metabolize half of the medication and remove it from your body.
Your age How your liver functions Your metabolism
Muscle relaxers stay in your system longer than 24 hours. If you must have an alcoholic beverage, it is best to wait 24 hours or longer after taking your last dose of the muscle relaxer to avoid any potentially harmful effects.
Can I take cyclobenzaprine if I had a glass of wine?
There is 1 alcohol/food/lifestyle interaction with cyclobenzaprine. Alcohol can increase the nervous system side effects of cyclobenzaprine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment.
You should avoid or limit the use of alcohol while being treated with cyclobenzaprine. Do not use more than the recommended dose of cyclobenzaprine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Switch to professional interaction data
Is 10 mg of cyclobenzaprine strong?
Cyclobenzaprine, once widely available under the trade name Flexeril and still available as the branded, extended-release formulation Amrix—is a muscle relaxant that is primarily used for the short-term treatment of muscle spasm and certain other painful musculoskeletal conditions.
- As a skeletal muscle relaxant, cyclobenzaprine is ineffective for people with muscle spasticity of spinal cord or cerebral disease origin.1 The recommended dose of immediate-release cyclobenzaprine is 5 to 10mg, three times a day, while that for extended-release versions is 15 to 30 mg, once a day.
- Cyclobenzaprine 10 mg dose is also available.
Maximum daily dose for either form is 30 mg over the course of 24 hours. Taking more may result in adverse Flexeril side effects or overdose.
How long does cyclobenzaprine 10mg last?
Cyclobenzaprine’s Effectiveness Timeframe Cyclobenzaprine works for 4-6 hours. However, the half-life of immediate-release cyclobenzaprine is 18 hours on average, with a range of 8-37 hours.
What happens if you drink alcohol with a muscle relaxer on an empty stomach?
Article at a Glance: – Important points to remember about alcohol and muscle relaxers include:
The term muscle relaxers refer to a broad category of drugs that relieve acute muscle pain or muscle spasmsCombining muscle relaxers with alcohol is not recommended because it can produce dangerous side effects and increase overdose riskExtreme dizziness, drowsiness, unusual behavior or memory problems may occur when drinking alcohol while using muscle relaxersAlcohol makes an overdose more likelyIf an overdose is suspected, contact medical help immediately
What not to mix with cyclobenzaprine?
Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication.
How many hours does cyclobenzaprine work?
Abstract – Background: Cyclobenzaprine hydrochloride is a muscle relaxant that is effective in improving muscle spasm, reducing local pain and tenderness, and increasing range of motion in acute, painful musculoskeletal conditions. Sedation is the most common adverse event associated with its use at the usual dosage of 10 mg TID.
Studies in healthy adults suggest that a lower dose may produce less sedation. Because cyclobenzaprine’s duration of action is 4 to 6 hours, reducing the dosing frequency to 10 mg BID would create a potentially painful untreated interval between doses. The alternative is administration of a lower dose (eg, 5 or 2.5 mg) TID.
Objective: These studies were designed to assess the efficacy and tolerability of cyclobenzaprine 2.5, 5, and 10 mg TID compared with placebo in patients with acute musculoskeletal spasm. Methods: In 2 randomized, double-blind, placebo-controlled, parallel-group trials conducted at primary care centers in the United States, adult patients with acute painful muscle spasm of the lumbar or cervical region were randomly assigned to receive treatment with 2.5, 5, or 10 mg cyclobenzaprine TID or placebo for 7 days (study 1: cyclobenzaprine 5 or 10 mg TID or placebo; study 2: cyclobenzaprine 2.5 or 5 mg TID or placebo).
- The primary efficacy measures were patient-rated clinical global impression of change, medication helpfulness, and relief from starting backache.
- Neither study included a nonsteroidal anti-inflammatory drug (NSAID) as an active control.
- Although physicians frequently prescribe an analgesic or NSAID in addition to cyclobenzaprine, these studies were not designed to assess whether adding cyclobenzaprine provides a benefit over that of an analgesic.
Results: One thousand four hundred five patients (737 study 1; 668 study 2), two thirds with low back pain and one third with neck pain, were randomized to treatment. Their mean age was 42 years, and approximately 89% were white. In both studies, patients receiving cyclobenzaprine 5 or 10 mg had significantly higher mean scores on the primary efficacy measures compared with those receiving placebo (study 1-P /= 1 adverse event was reported in 54.1%, 61.8%, and 35.4% of patients receiving cyclobenzaprine 5 or 10 mg or placebo, respectively, in study 1 and by 43.9%, 55.9%, and 35.4% of patients receiving cyclobenzaprine 2.5 or 5 mg or placebo, respectively, in study 2.
Adverse events were the primary reason for discontinuation of treatment in the cyclobenzaprine 5- and 10-mg groups in both studies. In study 2, ineffectiveness of therapy was the main reason for discontinuation of therapy in the group receiving cyclobenzaprine 2.5 mg. Conclusions: Cyclobenzaprine 2.5 mg TID was not significantly more effective than placebo.
The cyclobenzaprine 5- and 10-mg TID regimens were associated with significantly higher mean efficacy scores compared with placebo. Cyclobenzaprine 5 mg TID was as effective as 10 mg TID, and was associated with a lower incidence of sedation.
How long will I sleep with cyclobenzaprine?
The effects of Flexeril last for four to six hours.
Is cyclobenzaprine hard on the liver?
Introduction – Cyclobenzaprine is a centrally acting muscle relaxant closely related to the tricyclic antidepressants. Despite its similarity to tricyclic antidepressants, there is little evidence that cyclobenzaprine causes liver injury.
Can you drink coffee while taking cyclobenzaprine?
Summary Cyclobenzaprine is a skeletal muscle relaxant that works on the brainstem to treat muscle spasms of local origin. Brand Names Amrix, Fexmid, Flexeril Generic Name Cyclobenzaprine DrugBank Accession Number DB00924 Background Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 11 and has been available for human use since 1977.10 It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants – it differs from Amitriptyline by only a single double bond.11, 10 Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. Weight Average: 275.3874 Monoisotopic: 275.167399677 Chemical Formula C 20 H 21 N Synonyms
- (3-Dibenzocyclohepten-5-ylidene-propyl)-dimethyl-amine
- Ciclobenzaprina
- Cyclobenzaprine
- Cyclobenzaprinum
- N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External IDs
- MK-130
- TNX-102
Indication Cyclobenzaprine is indicated as a short-term (2-3 weeks) adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease, or spasticity in children with cerebral palsy.15, 16 Cyclobenzaprine is also occasionally used off-label for reducing pain and sleep disturbances in patients with fibromyalgia.9 Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. Build, train, & validate predictive machine-learning models with structured datasets. Associated Conditions
Muscle Spasms
Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more. Avoid life-threatening adverse drug events & improve clinical decision support.
Pharmacodynamics Cyclobenzaprine is a skeletal muscle relaxant that works on areas of the brainstem to reduce skeletal muscle spasm, though its exact pharmacodynamic behaviour is currently unclear.15, 16, 10 Despite its long half-life, it is relatively short-acting with a typical duration of action of 4-6 hours.10 Cyclobenzaprine has been reported to contribute to the development of serotonin syndrome when used in combination with other serotonergic medications.15, 16, 5 Symptoms of serotonin syndrome may include autonomic instability, changes to mental status, neuromuscular abnormalities, or gastrointestinal symptoms – treatment with cyclobenzaprine should be discontinued immediately if any of these reactions occur during therapy.15, 16 Mechanism of action The exact mechanism of action of cyclobenzaprine has not been fully elucidated in humans, and much of the information available regarding its mechanism has been ascertained from early animal studies.
There is some evidence that cyclobenzaprine exerts its effects at the supraspinal level, specifically within the locus coeruleus of the brainstem, with little-to-no action at neuromuscular junctions or directly on skeletal musculature 16, 10, Action on the brainstem is thought to result in diminished activity of efferent alpha and gamma motor neurons, likely mediated by inhibition of coeruleus-spinal or reticulospinal pathways, and ultimately depressed spinal cord interneuron activity.10 More recently it has been suggested that inhibition of descending serotonergic pathways in the spinal cord via action on 5-HT2 receptors may contribute to cyclobenzaprine’s observed effects.3, 10, 4
| Target | Actions | Organism |
|---|---|---|
| A 5-hydroxytryptamine receptor 2A | antagonist | Humans |
| U 5-hydroxytryptamine receptor 2B | antagonist | Humans |
| U 5-hydroxytryptamine receptor 2C | antagonist | Humans |
| U 5-hydroxytryptamine receptor 6 | antagonist | Humans |
| U Sodium-dependent serotonin transporter | inhibitor | Humans |
| U Sodium-dependent noradrenaline transporter | inhibitor | Humans |
| U 5-hydroxytryptamine receptor 7 | antagonist | Humans |
| U Toll-like receptor 4 | inhibitor | Humans |
| U Aldehyde oxidase | inhibitor | Humans |
Absorption The oral bioavailability of cyclobenzaprine has been estimated to be between 0.33 and 0.55.8, 11, 15 C max is between 5-35 ng/mL and is achieved after 4 hours (T max ).15, 10 AUC over an 8 hour dosing interval was reported to be approximately 177 ng.hr/mL.15 Volume of distribution The volume of distribution of cyclobenzaprine is approximately 146 L.11 The combination of high plasma clearance despite a relatively long half-life observed with cyclobenzaprine is suggestive of extensive tissue distribution.13, 8 Protein binding Cyclobenzaprine is approximately 93% protein bound in plasma.11 It has been identified as specifically having a high affinity for human serum albumin.12 Metabolism Cyclobenzaprine is extensively metabolized in the liver via both oxidative and conjugative pathways.15, 8, 10 Oxidative metabolism, mainly N-demethylation, is catalyzed primarily by CYP3A4 and CYP1A2 (with CYP2D6 implicated to a lesser extent) and is responsible for the major metabolite desmethylcyclobenzaprine 15, 1, 10,
Cyclobenzaprine also undergoes N-glucuronidation in the liver catalyzed by UGT1A4 and UGT2B10 2, and has been shown to undergo enterohepatic circulation.15, 8, 10 Hover over products below to view reaction partners Route of elimination After administration of a radio-labeled dose of cyclobenzaprine, 38-51% of radioactivity was excreted in the urine while 14-15% was excreted in the feces.16 Cyclobenzaprine is highly metabolized, with only approximately 1% of this same radio-labeled dose recovered in the urine as unchanged drug.
Metabolites excreted in the urine are likely water-soluble glucuronide conjugates.16 Half-life The effective half-life of cyclobenzaprine in young healthy subjects is approximately 18 hours.8, 15, 16 These values are extended in the elderly and those with hepatic insufficiency, with a mean effective half-life of 33.4 hours and 46.2 hours in these groups, respectively.8 Clearance The approximate plasma clearance of cyclobenzaprine is 0.7 L/min.8, 15, 16 Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Improve decision support & research outcomes with our structured adverse effects data.
Toxicity The oral LD 50 of cyclobenzaprine in mice and rats is 338 mg/kg and 425 mg/kg, respectively. Signs of overdose may develop rapidly after ingestion and commonly include significant drowsiness and tachycardia, with less common manifestations including tremor, agitation, ataxia, GI upset, and other CNS effects such as confusion and hallucinations.
Potentially critical manifestations, though rare, include cardiac arrest or dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome.15, 16 As the management of cyclobenzaprine overdose is complex and ever-changing, it is recommended that a poison control center be consulted prior to treatment.
Typical management involves gastrointestinal decontamination, close cardiac monitoring, and monitoring for signs of CNS or respiratory depression. As cyclobenzaprine exists in relatively low concentrations in plasma, monitoring of drug plasma levels should not guide management and dialysis is likely of no value.15, 16 Pathways Not Available Pharmacogenomic Effects/ADRs Not Available Drug Interactions This information should not be interpreted without the help of a healthcare provider.
If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
- Approved
- Vet approved
- Nutraceutical
- Illicit
- Withdrawn
- Investigational
- Experimental
- All Drugs
| Drug | Interaction |
|---|---|
| Integrate drug-drug interactions in your software | |
| 1,2-Benzodiazepine | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with 1,2-Benzodiazepine. |
| Abametapir | The serum concentration of Cyclobenzaprine can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Cyclobenzaprine can be increased when combined with Abatacept. |
| Abiraterone | The serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone. |
| Acenocoumarol | The metabolism of Acenocoumarol can be decreased when combined with Cyclobenzaprine. |
| Acetaminophen | The metabolism of Cyclobenzaprine can be decreased when combined with Acetaminophen. |
| Acetazolamide | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Acetazolamide. |
| Acetophenazine | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Acetophenazine. |
| Acyclovir | The metabolism of Cyclobenzaprine can be decreased when combined with Acyclovir. |
| Adalimumab | The metabolism of Cyclobenzaprine can be increased when combined with Adalimumab. |
Food Interactions
Avoid alcohol. Cyclobenzaprine is a central nervous system depressant which may be potentiated by the co-administration of alcohol.
Drug product information from 10+ global regions Our datasets provide approved product information including: dosage, form, labeller, route of administration, and marketing period. Access drug product information from over 10 global regions. Product Ingredients
| Ingredient | UNII | CAS | InChI Key |
|---|---|---|---|
| Cyclobenzaprine hydrochloride | 0VE05JYS2P | 6202-23-9 | VXEAYBOGHINOKW-UHFFFAOYSA-N |
Product Images International/Other Brands Flexiban (SIT) Brand Name Prescription Products
| Name | Dosage | Strength | Route | Labeller | Marketing Start | Marketing End | Region | Image |
|---|---|---|---|---|---|---|---|---|
| Amrix | Capsule, extended release | 30 mg/1 | Oral | Stat Rx USA | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | A-S Medication Solutions | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | Physicians Total Care, Inc. | 2009-04-16 | Not applicable | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | A-S Medication Solutions | 2007-10-02 | 2019-01-31 | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | Stat Rx USA | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 30 mg/1 | Oral | Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc | 2007-10-01 | 2015-12-31 | ||
| Amrix | Capsule, extended release | 30 mg/1 | Oral | Cephalon, LLC | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 30 mg/1 | Oral | Rebel Distributors | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | Rebel Distributors | 2007-10-01 | Not applicable | ||
| Amrix | Capsule, extended release | 15 mg/1 | Oral | Lake Erie Medical DBA Quality Care Products LLC | 2012-01-03 | 2019-10-11 |
Generic Prescription Products
| Name | Dosage | Strength | Route | Labeller | Marketing Start | Marketing End | Region | Image |
|---|---|---|---|---|---|---|---|---|
| Ag-cyclobenzaprine | Tablet | 10 mg | Oral | Angita Pharma Inc. | 2020-02-28 | Not applicable | ||
| Alti-cyclobenzaprine – Tab 10mg | Tablet | 10 mg | Oral | Altimed Pharma Inc. | 1995-12-31 | 2005-05-27 | ||
| Apo-cyclobenzaprine | Tablet | 10 mg | Oral | Apotex Corporation | 1995-12-31 | Not applicable | ||
| Auro-cyclobenzaprine | Tablet | 10 mg | Oral | Auro Pharma Inc | 2011-06-15 | Not applicable | ||
| Ava-cyclobenzaprine | Tablet | 10 mg | Oral | Avanstra Inc | 2011-10-11 | 2014-08-21 | ||
| Comfort Pac With Cyclobenzaprine | Kit; Tablet, film coated | 10 mg/1 | Oral | PD-Rx Pharmaceuticals, Inc. | 2013-07-15 | 2019-05-23 | ||
| Cyclobenzaprine | Tablet, film coated | 7.5 mg/1 | Oral | Rising Health, Llc | 2016-10-18 | Not applicable | ||
| Cyclobenzaprine | Tablet, film coated | 7.5 mg/1 | Oral | Proficient Rx LP | 2016-10-18 | Not applicable | ||
| Cyclobenzaprine | Tablet, film coated | 5 mg/1 | Oral | Direct Rx | 2016-12-16 | Not applicable | ||
| Cyclobenzaprine | Tablet, film coated | 7.5 mg/1 | Oral | All Pharma, Llc | 2016-10-18 | Not applicable |
Mixture Products
| Name | Ingredients | Dosage | Route | Labeller | Marketing Start | Marketing End | Region | Image |
|---|---|---|---|---|---|---|---|---|
| BENRELAX CÁPSULA BLANDA | Cyclobenzaprine hydrochloride (5 mg) + Clonixin lysine (125 mg) | Capsule, liquid filled | Oral | TECNOQUIMICAS S.A. | 2020-11-26 | Not applicable | ||
| CLONIXINATO / CICLOBENZAPRINA 125MG/5MG | Cyclobenzaprine hydrochloride (5 mg) + Clonixin lysine (125 mg) | Capsule, liquid filled | Oral | TECNOQUIMICAS S.A. | 2020-11-26 | Not applicable | ||
| Cyclo/Gaba 10/300 Pack | Cyclobenzaprine hydrochloride (10 mg/1) + Gabapentin (300 mg/1) | Kit | Oral | Tmig, Inc. | 2011-01-29 | Not applicable | ||
| DORIXINA® RELAX COMPRIMIDOS RECUBIERTOS | Cyclobenzaprine hydrochloride (5 mg) + Clonixin lysine (125 mg) | Tablet, coated | Oral | MEGALABS COLOMBIA S.A.S. | 2006-11-10 | Not applicable | ||
| NOpiod-TC | Cyclobenzaprine hydrochloride (7.5 mg/1) + Levomenthol (600 mg/1) + Lidocaine (600 mg/1) | Oral; Topical | Skya Health, LLC | 2020-05-15 | Not applicable | |||
| NOpioid-LMC | Cyclobenzaprine hydrochloride (7.5 mg/1) + Lidocaine (600 mg/1) + Menthol (600 mg/1) | Kit | Oral | Skya Health, LLC | 2020-05-15 | Not applicable | ||
| NOpioid-LMC | Cyclobenzaprine hydrochloride (7.5 mg/1) + Lidocaine (40 mg/1) + Menthol (40 mg/1) | Kit | Oral | Skya Health, LLC | 2020-05-15 | Not applicable |
Unapproved/Other Products
| Name | Ingredients | Dosage | Route | Labeller | Marketing Start | Marketing End | Region | Image |
|---|---|---|---|---|---|---|---|---|
| Cyclo/Mag | Cyclobenzaprine hydrochloride (1 g/1g) + Magnesium oxide (1 g/1g) | Kit | Oral | Living Well Pharmacy, Inc. | 2010-03-03 | Not applicable | ||
| Cyclo/Mag 10mg/200mg | Cyclobenzaprine hydrochloride (1 g/1g) + Magnesium oxide (1 g/1g) | Kit | Not applicable | Living Well Pharmacy, Inc. | 2010-02-17 | Not applicable | ||
| Cyclobenzaprine Hydrochloride | Cyclobenzaprine hydrochloride (10 mg/1) | Capsule, film coated, extended release | Oral | Sterling Knight Pharmaceuticals, Llc | 2016-10-31 | Not applicable | ||
| CyclobenzaprinePax | Cyclobenzaprine hydrochloride (10 mg/1) + Capsaicin (0.0375 g/100g) + Menthol (5 1/100g) | Kit | Oral; Topical | Solubiomix | 2015-09-05 | 2016-03-04 | ||
| Cyclopak | Cyclobenzaprine hydrochloride (5 mg/1) + Lidocaine (25 mg/1g) + Prilocaine (25 mg/1g) | Cream; Kit; Tablet, film coated | Oral; Topical | PureTek Corporation | 2020-11-30 | Not applicable | ||
| Cyclophene | Cyclobenzaprine hydrochloride (5.6 g/5.6g) | Kit | Topical | California Pharmaceuticals, Llc | 2016-01-01 | Not applicable | ||
| FlexePax | Cyclobenzaprine hydrochloride (10 mg/1) + Capsaicin (0.0375 g/100g) + Menthol (5 1/100g) | Kit | Oral; Topical | Basiem | 2015-08-27 | 2016-03-04 | ||
| Gapeam Budibac | Cyclobenzaprine hydrochloride (1 g/1g) + Amantadine hydrochloride (1 g/1g) + Baclofen (1 g/1g) + Bupivacaine hydrochloride anhydrous (1 g/1g) + Diclofenac sodium (1 g/1g) + Gabapentin (1 g/1g) + Pentoxifylline (1 g/1g) | Kit | Topical | Alvix Laboratories | 2014-12-05 | 2018-03-08 | ||
| NOpioid-TC | Cyclobenzaprine hydrochloride (7.5 mg/1) + Levomenthol (600 mg/1) + Lidocaine (600 mg/1) | Kit | Oral | Skya Health, LLC | 2020-05-15 | Not applicable | ||
| Tabradol | Cyclobenzaprine hydrochloride (0.25 g/0.25g) | Kit | Oral | California Pharmaceuticals, Llc | 2016-01-01 | Not applicable |
ATC Codes M03BX08 — Cyclobenzaprine
- M03BX — Other centrally acting agents
- M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
- M03 — MUSCLE RELAXANTS
- M — MUSCULO-SKELETAL SYSTEM
Drug Categories Chemical Taxonomy Provided by Classyfire Description This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Humans and other mammals
UNII 69O5WQQ5TI CAS number 303-53-7 InChI Key JURKNVYFZMSNLP-UHFFFAOYSA-N InChI InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3 IUPAC Name dimethyl(3- ]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine SMILES CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12 Synthesis Reference Villani, F.J.; US.
- Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos.1996 Jul;24(7):786-91.
- Lu D, Xie Q, Wu B: N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification. J Pharm Biomed Anal.2017 Oct 25;145:692-703. doi: 10.1016/j.jpba.2017.07.037. Epub 2017 Aug 4.
- Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol.1996 Sep 5;311(1):29-35.
- Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol.2003 Jan 1;458(1-2):91-9.
- Mestres J, Seifert SA, Oprea TI: Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther.2011 Nov;90(5):662-5. doi: 10.1038/clpt.2011.177. Epub 2011 Oct 5.
- Hutchinson MR, Loram LC, Zhang Y, Shridhar M, Rezvani N, Berkelhammer D, Phipps S, Foster PS, Landgraf K, Falke JJ, Rice KC, Maier SF, Yin H, Watkins LR: Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience.2010 Jun 30;168(2):551-63. doi: 10.1016/j.neuroscience.2010.03.067. Epub 2010 Apr 8.
- Obach RS, Huynh P, Allen MC, Beedham C: Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol.2004 Jan;44(1):7-19.
- Winchell GA, King JD, Chavez-Eng CM, Constanzer ML, Korn SH: Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol.2002 Jan;42(1):61-9. doi: 10.1177/0091270002042001007.
- Calandre EP, Rico-Villademoros F, Slim M: An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother.2015 Jun;16(9):1347-68. doi: 10.1517/14656566.2015.1047343.
- Cimolai N: Cyclobenzaprine: a new look at an old pharmacological agent. Expert Rev Clin Pharmacol.2009 May;2(3):255-63. doi: 10.1586/ecp.09.5.
- Brioschi TM, Schramm SG, Kano EK, Koono EE, Ching TH, Serra CH, Porta V: Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. Biomed Res Int.2013;2013:281392. doi: 10.1155/2013/281392. Epub 2013 Sep 16.
- Baig MH, Rahman S, Rabbani G, Imran M, Ahmad K, Choi I: Multi-Spectroscopic Characterization of Human Serum Albumin Binding with Cyclobenzaprine Hydrochloride: Insights from Biophysical and In Silico Approaches. Int J Mol Sci.2019 Feb 3;20(3). pii: ijms20030662. doi: 10.3390/ijms20030662.
- Hucker HB, Stauffer SC, Balletto AJ, White SD, Zacchei AG, Arison BH: Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Drug Metab Dispos.1978 Nov-Dec;6(6):659-72.
- CaymenChem: Cyclobenzaprine hydrochloride MSDS
- FDA Approved Drugs: Cyclobenzaprine
- DPD Approved Drugs: Cyclobenzaprine
External Links Human Metabolome Database HMDB0015060 KEGG Drug D07758 KEGG Compound C06931 PubChem Compound 2895 PubChem Substance 46508313 ChemSpider 2792 BindingDB 112774 RxNav 21949 ChEBI 3996 ChEMBL CHEMBL669 ZINC ZINC000000968263 Therapeutic Targets Database DAP000891 PharmGKB PA449160 RxList RxList Drug Page Drugs.com Drugs.com Drug Page PDRhealth PDRhealth Drug Page Wikipedia Cyclobenzaprine Clinical Trials
| Phase | Status | Purpose | Conditions | Count |
|---|---|---|---|---|
| 4 | Completed | Treatment | Acute Low Back Pain | 1 |
| 4 | Completed | Treatment | Pain / Spasms | 1 |
| 4 | Recruiting | Treatment | Back Pain Lower Back / Coronavirus Disease 2019 (COVID‑19) / Myofascial Pain Syndrome Lower Back | 1 |
| 4 | Recruiting | Treatment | Bariatric Surgery Candidates / Obesity, Morbid / Surgery | 1 |
| 4 | Terminated | Treatment | Fatigue / Fibromyalgia / Pain / Sleep | 1 |
| 3 | Completed | Treatment | Back pain / Neck Pain / Spasms | 1 |
| 3 | Completed | Treatment | Diseases of the Nervous System / Fibromyalgia / Musculoskeletal Disorders / Myofascial Pain Syndrome / Neuromuscular Disorders / Rheumatic Diseases | 1 |
| 3 | Completed | Treatment | Fibromyalgia | 1 |
| 3 | Completed | Treatment | Fibromyalgia, Primary | 1 |
| 3 | Completed | Treatment | Musculoskeletal Pain | 2 |
Manufacturers
- Anesta ag
- Actavis totowa llc
- Aurobindo pharma ltd
- Cadista pharmaceuticals inc
- Invagen pharmaceuticals inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Orit laboratories llc
- Pliva inc
- Ranbaxy laboratories ltd
- Sandoz inc
- Vintage pharmaceuticals inc
- Watson laboratories inc
- Mcneil pediatrics
Packagers
- 4uOrtho LLC
- Advanced Pharmaceutical Services Inc.
- Aidarex Pharmacuticals LLC
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apotheca Inc.
- AQ Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Aurobindo Pharma Ltd.
- Blenheim Pharmacal
- Breckenridge Pharmaceuticals
- Brighton Pharmaceuticals
- Bryant Ranch Prepack
- Cadista Pharmaceuticals Inc.
- Cardinal Health
- Cephalon Inc.
- Comprehensive Consultant Services Inc.
- Corepharma LLC
- Coupler Enterprises Inc.
- Dept Health Central Pharmacy
- DHHS Program Support Center Supply Service Center
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Dorx LLC
- ECR Pharmaceuticals
- Endo Pharmaceuticals Inc.
- Eurand Pharmaceuticals Inc.
- Fusion Pharmaceuticals LLC
- Golden State Medical Supply Inc.
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Innoviant Pharmacy Inc.
- Kaiser Foundation Hospital
- Keltman Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mckesson Corp.
- McNeil Laboratories
- Medisca Inc.
- Merck & Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mutual Pharmaceutical Co.
- Mylan
- Neighborcare Repackaging Inc.
- Nucare Pharmaceuticals Inc.
- Ortho Mcneil Janssen Pharmaceutical Inc.
- Palmetto Pharmaceuticals Inc.
- Patient First Corp.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Pliva Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Prescription Dispensing Service Inc.
- Qualitest
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Sandhills Packaging Inc.
- Sandoz
- Southwood Pharmaceuticals
- Spectrum Pharmaceuticals
- St Mary’s Medical Park Pharmacy
- Stat Rx Usa
- Stat Scripts LLC
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- United Research Laboratories Inc.
- Va Cmop Dallas
- Vangard Labs Inc.
- Victory Pharma
- Vintage Pharmaceuticals Inc.
- Watson Pharmaceuticals
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Capsule, extended release | Oral | 15 mg/1 |
| Capsule, extended release | Oral | 30 mg/1 |
| Tablet | Oral | 10 mg |
| Capsule, liquid filled | Oral | |
| Kit | Oral | |
| Kit | Not applicable | |
| Capsule, film coated, extended release | Oral | 10 mg/1 |
| Capsule, film coated, extended release | Oral | 5 mg/1 |
| Kit | Oral | 10 mg/1 |
| Powder | Not applicable | 1 g/1g |
| Tablet | Oral | 10 mg/1 |
| Tablet | Oral | 10 mg/10mg |
| Tablet | Oral | 5 mg/1 |
| Tablet | Oral | 7.5 mg/1 |
| Tablet, coated | Oral | 10 mg/1 |
| Tablet, film coated | Oral | 10 mg/1 |
| Tablet, film coated | Oral | 10 mg/301 |
| Tablet, film coated | Oral | 5 mg/1 |
| Cream; kit; tablet, film coated | Oral; Topical | |
| Kit | Topical | 5.6 g/5.6g |
| Kit; tablet, film coated | Oral | 10 mg/1 |
| Tablet, coated | Oral | 10 mg |
| Tablet, coated | Oral | 5 mg |
| Tablet, film coated | Oral | 7.5 mg/1 |
| Tablet, film coated | Oral | 10 mg |
| Tablet, film coated | Oral | 5 mg |
| Kit | Oral; Topical | |
| Tablet | Oral | |
| Kit | Topical | |
| Capsule, extended release | Oral | 15 mg |
| Tablet, coated | Oral | |
| Kit | Oral | 0.25 g/0.25g |
| Kit | Oral | 0.28 g/0.28g |
| Tablet | Oral | 5 mg |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Cyclobenzaprine hcl crystal | 273.88USD | g |
| Cyclobenzaprine hcl powder | 35.84USD | g |
| Fexmid 7.5 mg tablet | 4.18USD | tablet |
| Flexeril 5 mg tablet | 2.04USD | tablet |
| Flexeril 10 mg tablet | 1.74USD | tablet |
| Cyclobenzaprine HCl 5 mg tablet | 1.71USD | tablet |
| Cyclobenzaprine 5 mg tablet | 1.64USD | tablet |
| Cyclobenzaprine HCl 10 mg tablet | 0.47USD | tablet |
| Cyclobenzaprine 10 mg tablet | 0.41USD | tablet |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. Patents
| Patent Number | Pediatric Extension | Approved | Expires (estimated) | Region |
|---|---|---|---|---|
| US7544372 | No | 2009-06-09 | 2023-11-14 | |
| US7829121 | No | 2010-11-09 | 2023-11-14 | |
| US7820203 | No | 2010-10-26 | 2023-11-14 | |
| US7790199 | No | 2010-09-07 | 2023-11-14 | |
| US7387793 | No | 2008-06-17 | 2025-02-26 | |
| US9399025 | No | 2016-07-26 | 2023-11-14 | |
| US9375410 | No | 2016-06-28 | 2023-11-14 | |
| US8877245 | No | 2014-11-04 | 2023-11-14 |
State Solid Experimental Properties
| Property | Value | Source |
|---|---|---|
| melting point (°C) | 217 | FDA Label |
| water solubility | Freely Soluble | FDA Label |
| logP | 5.2 | Not Available |
| pKa | 8.47 | FDA Label |
Predicted Properties
| Property | Value | Source |
|---|---|---|
| Water Solubility | 0.00689 mg/mL | ALOGPS |
| logP | 4.73 | ALOGPS |
| logP | 4.61 | Chemaxon |
| logS | -4.6 | ALOGPS |
| pKa (Strongest Basic) | 9.76 | Chemaxon |
| Physiological Charge | 1 | Chemaxon |
| Hydrogen Acceptor Count | 1 | Chemaxon |
| Hydrogen Donor Count | Chemaxon | |
| Polar Surface Area | 3.24 Å 2 | Chemaxon |
| Rotatable Bond Count | 3 | Chemaxon |
| Refractivity | 102.62 m 3 ·mol -1 | Chemaxon |
| Polarizability | 32.94 Å 3 | Chemaxon |
| Number of Rings | 3 | Chemaxon |
| Bioavailability | 1 | Chemaxon |
| Rule of Five | Yes | Chemaxon |
| Ghose Filter | Yes | Chemaxon |
| Veber’s Rule | Yes | Chemaxon |
| MDDR-like Rule | No | Chemaxon |
Predicted ADMET Features
| Property | Value | Probability |
|---|---|---|
| Human Intestinal Absorption | + | 0.9941 |
| Blood Brain Barrier | + | 0.9512 |
| Caco-2 permeable | + | 0.8867 |
| P-glycoprotein substrate | Substrate | 0.7567 |
| P-glycoprotein inhibitor I | Inhibitor | 0.8563 |
| P-glycoprotein inhibitor II | Inhibitor | 0.6447 |
| Renal organic cation transporter | Inhibitor | 0.7955 |
| CYP450 2C9 substrate | Non-substrate | 0.7826 |
| CYP450 2D6 substrate | Substrate | 0.8918 |
| CYP450 3A4 substrate | Substrate | 0.7501 |
| CYP450 1A2 substrate | Inhibitor | 0.7324 |
| CYP450 2C9 inhibitor | Non-inhibitor | 0.9071 |
| CYP450 2D6 inhibitor | Inhibitor | 0.8933 |
| CYP450 2C19 inhibitor | Non-inhibitor | 0.9025 |
| CYP450 3A4 inhibitor | Non-inhibitor | 0.9158 |
| CYP450 inhibitory promiscuity | Low CYP Inhibitory Promiscuity | 0.6955 |
| Ames test | Non AMES toxic | 0.9132 |
| Carcinogenicity | Non-carcinogens | 0.8127 |
| Biodegradation | Not ready biodegradable | 0.8727 |
| Rat acute toxicity | 2.9697 LD50, mol/kg | Not applicable |
| hERG inhibition (predictor I) | Weak inhibitor | 0.7531 |
| hERG inhibition (predictor II) | Inhibitor | 0.6767 |
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. ( 23092397 ) Mass Spec (NIST) Not Available Spectra
| Spectrum | Spectrum Type | Splash Key |
|---|---|---|
| Predicted GC-MS Spectrum – GC-MS | Predicted GC-MS | Not Available |
| Predicted MS/MS Spectrum – 10V, Positive (Annotated) | Predicted LC-MS/MS | Not Available |
| Predicted MS/MS Spectrum – 20V, Positive (Annotated) | Predicted LC-MS/MS | Not Available |
| Predicted MS/MS Spectrum – 40V, Positive (Annotated) | Predicted LC-MS/MS | Not Available |
| Predicted MS/MS Spectrum – 10V, Negative (Annotated) | Predicted LC-MS/MS | Not Available |
| Predicted MS/MS Spectrum – 20V, Negative (Annotated) | Predicted LC-MS/MS | Not Available |
| Predicted MS/MS Spectrum – 40V, Negative (Annotated) | Predicted LC-MS/MS | Not Available |
Is alcohol a natural muscle relaxer?
5. Alcohol relaxes the muscles – Have you ever drunk just a little too much and found that your muscles become more relaxed than normal? This is to do with the fact that alcohol slows the function of nerves which spread messages throughout the body. As a result, coordination, balance, reaction time and accuracy of movement can all be affected.
Does cyclobenzaprine make you groggy the next day?
Precautions – It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. If your condition does not improve within 2 or 3 weeks, or if it becomes worse, check with your doctor.
- Do not use the extended-release capsules if you have used an MAO inhibitor (MAOI) such as Eldepryl®, Marplan®, Nardil®, or Parnate® within 14 days of each other.
- Check with your doctor right away if you have anxiety, restlessness, a fast heartbeat, fever, sweating, muscle spasms, twitching, nausea, vomiting, diarrhea, or see or hear things that are not there.
These may be symptoms of a serious condition called serotonin syndrome. Your risk may be higher if you also take certain other medicines that affect serotonin levels in your body. This medicine will add to the effects of alcohol and other CNS depressants (medicines that slow down the nervous system, possibly causing drowsiness).
Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds, sedatives, tranquilizers, or sleeping medicine, prescription pain medicine or narcotics, medicine for seizures or barbiturates, other muscle relaxants, or anesthetics, including some dental anesthetics.
Check with your doctor before taking any of the above while you are using this medicine. This medicine may cause some people to have blurred vision or to become drowsy, dizzy, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert and able to see well.
Can I take cyclobenzaprine during the day?
Cyclobenzaprine is a reasonable first choice because it’s a cheap generic. But it has more potential for side effects, like sedation. This limits how you can use it during the day. Cyclobenzaprine may also cause dry mouth, especially in older adults.
Why should you not take cyclobenzaprine for more than 3 weeks?
PHILADELPHIA – Office visits for ongoing prescribing of skeletal muscle relaxant drugs tripled from 2005 to 2016, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. Moreover, in 2016, nearly 70 percent of patients prescribed muscle relaxants were simultaneously prescribed an opioid — a combination that has the potential to cause dangerous interactions.
The researchers also found that muscle relaxants were prescribed disproportionately to older adults during this time period, despite national guidelines warning that this class of drugs should almost always be avoided in patients who are 65 and older. The results were published today in JAMA Network Open,
“There are few studies on the short-term efficacy and safety of skeletal muscle relaxants, and almost no data on their long-term effects, so it is very concerning that patients, and particularly older adults, are using these drugs for an extended period of time,” said Charles E.
- Leonard, PharmD, MSCE, an assistant professor of Epidemiology.
- Providers seem to be reaching for them despite incomplete information on their potential benefits and risks.” Skeletal muscle relaxants are drugs that were approved years ago for short-term treatment of muscle spasms and back pain, and are used today, without good evidence, to treat chronic pain and other conditions.
Recommendations generally limit the use of these drugs to a maximum of three weeks, since they have not been shown to work for muscle spasms beyond that duration, and they can cause serious side effects including falls, fractures, vehicle crashes, abuse, dependence, and overdose.
- Due to these risks, muscle relaxants should be avoided altogether in elderly patients, according to guidelines from the American Geriatrics Society.
- Despite these concerns, Leonard and his colleagues hypothesized that the growing opioid epidemic may have led clinicians to prescribe muscle relaxants as an alternative to opioids for long-term pain management.
To measure national trends in muscle relaxant prescribing, the researchers analyzed publicly-available 2005–2016 data from the National Ambulatory Medical Care Survey. NAMCS is a U.S.-based annual survey of non-federally funded office-based physicians engaged in direct patient care.
The researchers examined the total number of visits per year, and stratified counts by the muscle relaxant agent, whether the drug was newly prescribed or continued therapy, as well as the race, ethnicity, and sex of the patient, and the region of the visit. From 2005 to 2016, the number of office visits resulting in new muscle relaxant prescriptions remained stable at approximately 6 million per year, while office visits for continued muscle relaxant drug therapy tripled — from 8.5 million in 2005 to 24.7 million in 2016.
Worryingly, older adults accounted for 22.2 percent of all muscle relaxant visits in 2016, even though this group accounted for just 14.5 percent of the U.S. population. Also of concern, in 2016, 67 percent of the continued muscle relaxant visits also recorded therapy with an opioid.
The U.S. Food and Drug Administration warns against use of co-prescribing of these medications, because of the risk of serious side effects, including slowed or difficult breathing, and death. “For older adults, I think the message should be to avoid using muscle relaxants, especially when we consider the side effects and increased risk of falls and fractures, and to find alternatives for pain management,” said the study’s first author Samantha Soprano, MPH, a research coordinator and student in Penn’s Master of Behavioral and Decision Sciences program.
Leonard added that, in addition to potential adverse effects, muscle relaxants may not be any more effective in managing pain than medications like Tylenol or Advil. Past studies examining muscle relaxants found they were more efficacious than a placebo, but they were not compared to other therapies.
- Further research is needed to determine more detailed information about the effects of muscle relaxants, particularly when used for longer periods of time, since their use is so widespread, Leonard said.
- Additionally, doctors need better, safer options for managing patients’ pain.
- Muscle relaxants’ place in therapy is really limited.
Based on most guidelines, they’re normally reserved as second- or third-line therapies,” Leonard said. “Our findings suggest that prescribers may be reaching for these drugs sooner than that.” Other Penn authors on this study include Sean Hennessy, PharmD, PhD, and Warren B.
- Bilker, PhD.
- This research was supported by funding from the National Institutes of Health.
- Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care.
- Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $9.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751.
Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others. Penn Medicine is powered by a talented and dedicated workforce of more than 47,000 people.
The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.
In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.
Does cyclobenzaprine affect sleep quality?
Key takeaways: –
Patients with fibromyalgia receiving cyclobenzaprine demonstrated less pain compared with patients receiving placebo.Patients receiving cyclobenzaprine also had improved sleep quality and reduced fatigue.
Patients with fibromyalgia who receive a sublingual tablet form cyclobenzaprine experience reduced daily pain, and improved sleep quality, compared with those who received placebo, according to a press release from the drug’s manufacturer. “There continues to be a pressing need for new, safe and more tolerable drugs to treat patients with fibromyalgia,” Seth Lederman, MD, CEO of Tonix Pharmaceuticals, said in the press release. Patients with fibromyalgia who receive a sublingual tablet form cyclobenzaprine experience reduced daily pain, and improved sleep quality, compared with those who received placebo, according to a press release. Image: Adobe Stock Lederman presented the early efficacy and safety data for TNX-102 SL, Tonix Pharmaceuticals’ patented form of the drug, at the International Congress on Controversies in Fibromyalgia meeting.
- According to the release, the phase 3 RELIEF trial showed that patients receiving TNX-102 SL were “significantly” more likely to have reduced daily pain attributed to fibromyalgia, compared with those in the placebo group ( P =,01).
- The primary endpoint for the study was a 30% or greater pain responder analysis for the test therapy compared to placebo.
In all, 47% of patients responded to TNX-102 SL, while 35% responded to placebo ( P =,006). Additionally, the 5.6 mg TNX-102 SL group achieved success in secondary endpoints, including improved sleep quality, reduced fatigue and “fibromyalgia-specific global symptomatic and functional recovery,” according to the release.
TNX-102 SL was also well-tolerated, the company said, with both groups demonstrating similar rates of discontinuation. The most common adverse events in patients who received TNX-102 SL was hypoesthesia. The final enrollment for the study was 503 participants. Topline data from the RELIEF Study is due in the fourth quarter of 2023, according to the release.
ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on, We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected],
Why can’t you drive on cyclobenzaprine?
Precautions – Drug information provided by: Merative, Micromedex ® It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it.
If your condition does not improve within 2 or 3 weeks, or if it becomes worse, check with your doctor. Do not use the extended-release capsules if you have used an MAO inhibitor (MAOI) such as Eldepryl®, Marplan®, Nardil®, or Parnate® within 14 days of each other. Check with your doctor right away if you have anxiety, restlessness, a fast heartbeat, fever, sweating, muscle spasms, twitching, nausea, vomiting, diarrhea, or see or hear things that are not there.
These may be symptoms of a serious condition called serotonin syndrome. Your risk may be higher if you also take certain other medicines that affect serotonin levels in your body. This medicine will add to the effects of alcohol and other CNS depressants (medicines that slow down the nervous system, possibly causing drowsiness).
Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds, sedatives, tranquilizers, or sleeping medicine, prescription pain medicine or narcotics, medicine for seizures or barbiturates, other muscle relaxants, or anesthetics, including some dental anesthetics.
Check with your doctor before taking any of the above while you are using this medicine. This medicine may cause some people to have blurred vision or to become drowsy, dizzy, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert and able to see well.
Does cyclobenzaprine affect serotonin levels?
Cyclobenzaprine, presumably due to its tricyclic antidepressant properties, can cause symptoms of serotonin excess including psychosis, myoclonus and dystonia. All patients naïve to cyclobenzaprine should be warned and monitored initially for symptoms of serotonin excess.
What to avoid while taking cyclobenzaprine?
Cyclobenzaprine interacts with many medications and substances. These include medications that raise serotonin levels like antidepressants. It can also interact with medications and substances that slow down brain activity. These include benzodiazepines, opioids, and alcohol.
Can you drink alcohol while taking cyclobenzaprine and melatonin?
Drug and food interactions – Alcohol can increase the nervous system side effects of cyclobenzaprine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with cyclobenzaprine.
- Do not use more than the recommended dose of cyclobenzaprine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you.
- Talk to your doctor or pharmacist if you have any questions or concerns.
- Switch to professional interaction data Consumer information for this interaction is not currently available.
MONITOR: Oral caffeine may significantly increase the bioavailability of melatonin. The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism. After administration of melatonin 6 mg and caffeine 200 mg orally (approximately equivalent to 1 large cup of coffee) to 12 healthy subjects, the mean peak plasma concentration (Cmax) of melatonin increased by 137% and the area under the concentration-time curve (AUC) increased by 120%.
- The metabolic inhibition was greater in nonsmokers (n=6) than in smokers (n=6).
- The greatest effect was seen in subjects with the *1F/*1F genotype (n=7), whose melatonin Cmax increased by 202%.
- The half-life did not change significantly.
- The clinical significance of this interaction is unknown.
- According to some authorities, alcohol may reduce the effect of melatonin on sleep.
The mechanism of this interaction is not fully understood. In addition, CYP450 1A2 inducers like cigarette smoking may reduce exogenous melatonin plasma levels. In a small clinical trial (n=8), habitual smokers had their melatonin plasma levels measured two times, each after a single oral dose of 25 mg of melatonin.
They had smoked prior to the first measurement but had not smoked for 7 days prior to the second. Cigarette smoking significantly reduced melatonin plasma exposure (AUC) as compared to melatonin levels after 7 days of smoking abstinence (7.34 +/- 1.85 versus 21.07 +/- 7.28 nmol/L*h, respectively). MANAGEMENT: Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.
Consumption of alcohol should be avoided when taking melatonin.
How long will I sleep with cyclobenzaprine?
The effects of Flexeril last for four to six hours.
Is 10 mg of cyclobenzaprine strong?
Cyclobenzaprine, once widely available under the trade name Flexeril and still available as the branded, extended-release formulation Amrix—is a muscle relaxant that is primarily used for the short-term treatment of muscle spasm and certain other painful musculoskeletal conditions.
As a skeletal muscle relaxant, cyclobenzaprine is ineffective for people with muscle spasticity of spinal cord or cerebral disease origin.1 The recommended dose of immediate-release cyclobenzaprine is 5 to 10mg, three times a day, while that for extended-release versions is 15 to 30 mg, once a day. Cyclobenzaprine 10 mg dose is also available.
Maximum daily dose for either form is 30 mg over the course of 24 hours. Taking more may result in adverse Flexeril side effects or overdose.